An observational study in Rheumatoid Arthritis (RA), sponsored by University Hospital, Montpellier. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-01.
Sponsored by University Hospital, Montpellier · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier — 6 open to participants now, 6 under way, 1 of them phase 3. Arthritis, Rheumatoid · University Hospital, Montpellier.
Among the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, this one is the 8th largest by planned enrollment of the 12 observational ones that give a count, is the only one that started in 2025, is one of 12 observational ones, and was the 26th registered.
3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →6 of the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier are open now, in 2 countries. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Montpellier · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.
Median enrollment 87 across the 15 interventional studies, 182 across the 12 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
University Hospital, Montpellier is the lead sponsor of 1,264 studies on the registry; 226 are open to participants now.
1 of the studies in Arthritis, Rheumatoid by University Hospital, Montpellier that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Arthritis, Rheumatoid by University Hospital, Montpellier, from their registry updates:
This tab as a report to print or save as PDF → With an account.
PROMESS 1 is a multicenter cohort interventional study aiming at analyzing the factors associated with the risk of developing clinical arthritis among exposures or combinations of exposures in patients at risk of rheumatoid arthritis (RA), as they have high levels of anti-citrullinated peptides autoantibodies (ACPA ≥2 N).
The primary endpoint is the occurrence of clinical arthritis confirmed by ultrasound at two years of following for the subject's groups at risk of RA.
This may be explained by the following exposures or combinations of exposures: smoking, occupational exposure, physical activity, diet, hormonal exposure, drug exposure, trauma and psychological stress.
Other factors may also explain the occurrence of clinical arthritis:
This is a multicenter interventional cohort study. The goal of this cohort is to analyze the factors associated with the risk of developing clinical arthritis, considering individual or combined exposures, in patients at high risk of rheumatoid arthritis (RA).
Four groups of adults will be included:
The primary endpoint is the occurrence of clinical arthritis, confirmed by ultrasound, after two years of follow-up in the at-risk RA groups (Groups 1 \& 2).
This may be explained by the following exposures or their combinations: smoking, occupational exposure, physical activity, diet, hormonal exposure, drug exposure, trauma and psychological stress...
Other factors that may contribute to the occurrence of clinical arthritis include:
The controls groups (groups 3\&4) will allow for a cross-sectional analysis, comparing at-risk RA subjects with healthy individuals who share the same genetic background. They will have a single visit at baseline without follow-up.
However, the at-risk RA groups (groups 1 \& 2) will have four visits (M0, M6, M12 et M24), plus an additional visit in case of suspected arthritis. In addition to routine care examinations performed in RA risk situations, subjects will undergo blood and stool sample collection at baseline and at one year.
All subjects regardless of group, will undergo the following baseline assessments: MRI of the dominant hand or painful hand, a lactulose-mannitol absorption test (to assess intestinal permeability), hair and saliva collection, a Schirmer test, and, in some centers, an induced sputum test (to assess pulmonary mucosa). Ultrasound of the hands and feet, as well as specific questionnaires assessing the exposome, will be conducted at all visits.
Exploratory objectives: blood and pulmonary immunobiological characteristics (immunophenotyping on fresh blood in selected centers); environmental exposure assessed with partial addresses (street and city names of homes and workplaces); psychological, psychiatric and psychosomatic factors. Exploratory predictive modelling (penalized regression, random forest, gradient boosting) will complement the confirmatory analyses after database lock.
The patients will be recruted during consultation or hospitalization.
Inclusion Criteria:
Exclusion Criteria:
Groupe1-2-3:
All groups:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A total of 50 subjects will be recruited: individuals with ACPA≥2 N and clinically suspect arthralgia (CSA criteria ≥4) or those with ACPA≥N and rheumatoid factor≥2N along with clinically suspect arthralgia (CSA criteria ≥4). These subjects have an estimated 50% risk of progression to RA within 2 years.
Biological: Blood test · Biological: Urine test · Other: stool collection · Other: saliva collection · Other: Induced expectoration · Other: Hair and nails sampling · Other: Schirmer test · Radiation: Ultrasound of hands and feet · Radiation: MRI Contrast · Other: Patient questions · Diagnostic Test: Dental panoramic X-ray · Other: Consultation with a psychologist in certain centers · Other: Measurement of heart rate variability. · Behavioral: Behavioral: semi-structured psychological interview (1 h, teleconsultation)
A total of 50 subjects will be recruited: individuals with ACPA≥2 N who do not meet the criteria for clinically suspect arthralgia (CSA criteria \<4) or those with ACPA≥N and rheumatoid factor≥2N who also do not meet the criteria for clinically suspect arthralgia (CSA criteria \<4). These subjects have an estimated 30% risk of progression to RA within 2 years.
Biological: Blood test · Biological: Urine test · Other: stool collection · Other: saliva collection · Other: Induced expectoration · Other: Hair and nails sampling · Other: Schirmer test · Radiation: Ultrasound of hands and feet · Radiation: MRI Contrast · Other: Patient questions · Diagnostic Test: Dental panoramic X-ray · Other: Consultation with a psychologist in certain centers · Other: Measurement of heart rate variability. · Behavioral: Behavioral: semi-structured psychological interview (1 h, teleconsultation)
A total 25 subjects will be recruited: asymptomatic subjects (CSA criteria \<4) with a family history of RA in a first-degree relative (negative controls).
Biological: Blood test · Biological: Urine test · Other: stool collection · Other: saliva collection · Other: Induced expectoration · Other: Hair and nails sampling · Other: Schirmer test · Radiation: Ultrasound of hands and feet · Radiation: MRI Contrast · Other: Patient questions · Other: Consultation with a psychologist in certain centers · Other: Measurement of heart rate variability.
A total of 25 subjects will be recruited: individuals with RA diagnosed at polyarthritis onset (diagnosis \<6 months) who have not yet been treated, with ACPA≥2 N or ACPA≥N and rheumatoid factor≥2N (positive controls).
Biological: Blood test · Biological: Urine test · Other: stool collection · Other: saliva collection · Other: Induced expectoration · Other: Hair and nails sampling · Other: Schirmer test · Radiation: Ultrasound of hands and feet · Radiation: MRI Contrast · Other: Patient questions · Diagnostic Test: Dental panoramic X-ray · Other: Consultation with a psychologist in certain centers · Other: Measurement of heart rate variability.
A total of 90 ml of blood will be collected while fasting, using the following tubes: one PAXGene Blood RNA Tube, one PAXGene Blood DNA Tube, five 5 mL serum tubes, five 5 mL EDTA tubes and one 2 mL EDTA tube for microbiota DNA analysis.
Urine will be collected, while fasting and after the administration of lactulose/ mannitol to assess intestinal permeability.
Stool samples will be collected either at the hospital or at home using a dedicated kit.
5 ml of saliva will be collected and saliva microbiome DNA will be collected using an OMNIgene Oral kit.
inhalation of salbutamol, measurement of peak expiratory flow by screening spirometry (15 min later), inhalation of a hypertonic aerosol for 3 periods of 7 min. At the end of each inhalation period, the induced sputum is collected and the peak expiratory flow is measured to prevent possible bronchospasms
Hair and nails samples will be collected.
To assess of tear secretion
To assess the risk of RA in high-risk subjects by evaluating for synovitis, tenosynovitis, or intermetatarsal-phalangeal bursitis.
MRI of the dominant or painful hand will be performed to assess the risk of RA in high-risk subjects.
Self-questionnaires will assess factors such as ethnic origin, family history of RA, diet, physical activity, exposure to toxic substances, pollution, occupational exposures, psychological and clinical factors.
Performed as part of routine care to assess dental health
The short-CTQ will be completed during this consultation, only in centers offering consultations with a psychologist.
The patient will wear a belt throughout the visit 1. At the end of the day, the heart rate variability data measured by the belt will be recorded in the CRF (RR interval, heart rate variability SDNN, RMSSD, and LF/HF sympathovagal balance).
At W0 on V1 an affective touch perception test (15 min), self-assessment of perceived RA risk, satisfaction and impact questionnaire. at week 26, optionally completed by an in-person session (self-drawing, Rorschach test, Thematic Apperception Test; 1 h)
Risk of developing clinical arthritis
To analyze the factors associated with the risk of developing clinical arthritis confirmed by ultrasound among exposures or combinations of exposures in patients at high risk of RA.
Time frame: From the baseline to the end of the follow-up at 2 years
Quantitative difference in Food Frequency Questionnaire (FFQ) between the 4 groups of subjects included, varying from never or rarely to daily or multiple times per day.
Time frame: At baseline
Quantitative difference in National Observatory for Physical Activity and Sedentariness -Physical Activity Questionnaire (ONAPS-PAQ) expressed in MET (Metabolic Equivalent of Task) per week between the 4 groups of subjects included.
Time frame: At baseline
Quantitative difference in patient-reported exposure outcome Alcohol and Substance Involvement Screening Test (ASSIST) score between the 4 groups of subjects included.
The score varies from 0 to 36 to each substance with higher score indicates greater substance-related risk and the need for stronger intervention strategies.
Time frame: At baseline
Quantitative difference in Fagerström Test for Nicotine Dependence (FTND) score between the 4 groups of subjects included.
The score varies from 1 to 6 with higher score indicate greater nicotine dependence.
Time frame: At baseline
Compare the exposure to pollution between the 4 groups of subjects included. "Exposure to pollution will be assessed by cross-referencing residential addresses with the Chimère database.
Time frame: At baseline
Qualitative difference in a self-report integrated questionnaire for diagnosis of all functional gastrointestinal disorders in adults between the 4 groups of subjects included.
Time frame: At baseline
Quantitative difference in patient-reported Francis score for Irritable Bowel Syndrome (IBS) between the 4 groups of subjects included.
The score varies from 0 to 100 with higher score means severe IBS.
Time frame: At baseline
Qualitative difference in patient-reported clinical outcome of Sleep Apnea (Berlin questionnaire) between the 4 groups of subjects included.
It is composed of 3 categories of questions, if 2 or more categories are positive it means a high risk of apnea.
Time frame: At baseline
Quantitative difference in Visual Analog Scale (VAS) score for patient's pain between the 4 groups of subjects included.
The score varies from 0 to 100 with higher score means worst pain possible.
Time frame: At baseline
Quantitative difference in Visual Analog Scale (VAS) score for patient's fatigue between the 4 groups of subjects included.
The score varies from 0 to 100 with higher score means extreme fatigue.
Time frame: At baseline
Quantitative difference in Visual Analog Scale (VAS) score for patient's disease activity between the 4 groups of subjects included.
The score varies from 0 to 100 with higher score means complete Limitation (Unable to Perform Any Activity).
Time frame: At baseline
Quantitative difference in Visual Analog Scale (VAS) score for disease activity on the opinion of the physician between the 4 groups of subjects included.
The score varies from 0 to 100 with higher score means complete Limitation (Unable to Perform Any Activity).
Time frame: At baseline
Quantitative difference in Pichot Fatigue Scale score between the 4 groups of subjects included.
The score varies from 0 to 32 with higher score means severe fatigue.
Time frame: At baseline
Quantitative difference in State-Trait Anxiety Inventory (STAI) score between the 4 groups of subjects included.
The score varies from 20 to 80 with higher score means high anxiety.
Time frame: At baseline
Quantitative difference in patient-reported outcome Posttraumatic Stress Disorder Checklist (PCL-5) score between the 4 groups of subjects included,
The score varies from 0 to 80 with higher score means very severe symptoms (Likely posttraumatic stress disorder (PTSD)).
Time frame: At baseline
Quantitative difference in patient-reported outcome heath survey Short Form-12 (SF-12) version 2 with Physical Component Summary (PCS) and Mental Component Summary (MCS) scores between the 4 groups of subjects included
The mean is 50 for each score with a standard deviation of 10, a higher score means better health status.
Time frame: At baseline
Quantitative difference in Insomnia Severity Index (ISI) score between the 4 groups of subjects included
The score varies from 0 to 28 with higher score means Severe insomnia.
Time frame: At baseline
Quantitative difference in Pain Catastrophizing Scale (PCS) score between the 4 groups of subjects included
The score varies from 0 to 52 with higher score means High pain catastrophizing.
Time frame: At baseline
Quantitative difference in Rheumatoid factor (FR) auto-antibody level between the 4 groups of subjects included.
Expressed in IU/ml (International Units per Milliliter)
Time frame: At baseline
Quantitative difference Anti-Citrullinated Peptide Antibodies (ACPA) level between the 4 groups of subjects included.
Expressed in IU/ml (International Units per Milliliter).
Time frame: At baseline
Quantitative difference in C-reactive protein (CRP) level between the 4 groups of subjects included.
Expressed in mg/L (milligram per liter)
Time frame: At baseline
Quantitative difference in Neutrophils values between the 4 groups of subjects included.
Expressed in cells/µL (microliter)
Time frame: At baseline
Quantitative difference in lymphocytes values between the 4 groups of subjects included.
Expressed in cells/µL (microliter)
Time frame: At baseline
Quantitative difference in Platelets (PLT) between the 4 groups of subjects included.
Expressed in platelets/µL (microliter)
Time frame: At baseline
Clinical arthritis and Clinically Suspected Arthralgias (CSA).
Assess the incidence of clinical arthritis in high-risk RA patients overall (group 1 and 2) and in subgroups according to the presence or absence of CSA and the auto-antibody profile at inclusion. The clinical arthritis is detected by the presence of joints swelling in at least 1 of the 44 joints swelling and confirmed by ultrasound.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in Visual Analog Scale (VAS) score for patient's pain between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 0 to 100 with higher score means worst pain possible. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in Visual Analog Scale (VAS) score for patient's fatigue between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 0 to 100 with higher score means extreme fatigue. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in Visual Analog Scale (VAS) score for patient's disease activity between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 0 to 100 with higher score means complete Limitation (Unable to Perform Any Activity). Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in Visual Analog Scale (VAS) score for disease activity on the opinion of the physician between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 0 to 100 with higher score means complete Limitation (Unable to Perform Any Activity). Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in Pichot Fatigue Scale score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 0 to 32 with higher score means severe fatigue. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in State-Trait Anxiety Inventory (STAI) score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 20 to 80 with higher score means high anxiety. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in patient-reported outcome Posttraumatic Stress Disorder Checklist (PCL-5) score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 0 to 80 with higher score means very severe symptoms (Likely posttraumatic stress disorder (PTSD). Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in patient-reported outcome heath survey Short Form-12 (SF-12) version 2 with Physical Component Summary (PCS) and Mental Component Summary (MCS) scores between the patients who developed clinical arthritis during the 2-year f
The mean is 50 for each score and a standard deviation of 10, a higher score means better health status. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in Insomnia Severity Index (ISI) score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 0 to 28 with higher score means Severe insomnia. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in Pain Catastrophizing Scale (PCS) score between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
The score varies from 0 to 52 with higher score means High pain catastrophizing. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in tender joints count between the patients who developed clinical arthritis during the 2-year follow-up and those who did not, among 44 joints across the body.
The score varies from 0 to 44 with higher score means more active inflammatory joint disease. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Quantitative difference in tenosynovitis count between the patients who developed clinical arthritis during the 2-year follow-up and those who did not, among 16 flexor and extensor finger's tendons.
The score varies from 0 to 44 with higher score means more active inflammatory joint disease. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Quantitative difference in difficulties of making a fist between the patients who developed clinical arthritis during the 2-year follow-up and those who did not. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Quantitative difference in tenosynovitis between the patients who developed clinical arthritis during the 2-year follow-up and those who did not detected by ultrasound. Relate this outcome to the risk of developing clinical arthritis
Time frame: Baseline, week 26; week 52 and week 104 visit
Quantitative difference in Rheumatoid factor (FR) auto-antibody level between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Expressed in IU/ml (International Units per Milliliter).Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Quantitative difference in Anti-Citrullinated Peptide Antibodies (ACPA) level between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Expressed in IU/ml (International Units per Milliliter) Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Quantitative difference in C-reactive protein (CRP) level between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Expressed in mg/L (milligram per liter) Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Quantitative difference in Neutrophils values between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Expressed in cells/µL (microliter).Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Quantitative difference in lymphocytes values between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Expressed in cells/µL (microliter). Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Quantitative difference in Platelets (PLT) between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Expressed in platelets/µL (microliter), Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Proportion of patients with ultrasound synovitis in the 2 groups at high-risk of rheumatoid factor (RA) (group 1 and 2).
Detected by ultrasound in mode B and Doppler on the hand's and feet's articulations with semi-quantitative gradation according to Outcome Measures in Rheumatology (OMERACT) recommendations, between the patients who developed clinical arthritis during the 2-year follow-up and those who did not. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Proportion of patients with ultrasound tenosynovitis in the 2 groups at high-risk of rheumatoid factor (RA) (group 1 and 2).
Detected by ultrasound in mode B and Doppler on the hand's and feet's articulations with semi-quantitative gradation according to Outcome Measures in Rheumatology (OMERACT) recommendations, between the patients who developed clinical arthritis during the 2-year follow-up and those who did not. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline, week 26, week 52 and week 104 visit
Proportion of patients with ultrasound synovitis in the 4 groups of subjects included.
Detected by ultrasound in mode B and Doppler on the hand's and feet's articulations with semi-quantitative gradation according to Outcome Measures in Rheumatology (OMERACT) recommendations. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Proportion of patients with ultrasound tenosynovitis in the 4 groups of subjects included.
Detected by ultrasound in mode B and Doppler on the hand's and feet's articulations with semi-quantitative gradation according to Outcome Measures in Rheumatology (OMERACT) recommendations. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in synovitis between the 4 groups of subjects included.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in bone oedemes between the 4 groups of subjects included.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in pinch between the 4 groups of subjects included.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in erosion between the 4 groups of subjects included.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in tenosynovitis between the 4 groups of subjects included, between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in synovitis between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in bone oedemes between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in pinch between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in erosion between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Quantitative difference in tenosynovitis between the patients who developed clinical arthritis during the 2-year follow-up and those who did not.
Detected by Magnetic Resonance Imaging (MRI) on the dominant hand or the most painful hand. Relate this outcome to the risk of developing clinical arthritis.
Time frame: Baseline
Analyzing heart rate variability as a risk factor for developing RA
Measurement of heart rate variability in high-risk patients (group 1 + group 2) for RA
Time frame: Baseline
Analyze environmental factors associated with the risk of developing clinical arthritis.
Exposure will be assessed using partial addresses
Time frame: Baseline, week 26, week 52 and week 104 visit
Association between comorbidities and medical history
(CNAM pathology mapping) and drug exposure (SNDS dispensing data) and the risk of clinical arthritis in Groups 1 and 2." Time frame: SNDS linkage at end of study.
Time frame: From the baseline to the end of the follow-up at 2 years
Association between psychological, psychiatric and psychosomatic factors
(BDI, MAIA, QSSP, TAS-20, Cambridge Depersonalization Scale, DES, psychological pain VAS, RFQ-B, affective touch perception test) and the risk of clinical arthritis in Groups 1 and 2, and comparison between groups.
Time frame: baseline, week 26, week 52 and week 104, depending on the instrument.
Association between blood and pulmonary immunobiological characteristics
(immunophenotyping on fresh blood, induced sputum) and the risk of clinical arthritis in Groups 1 and 2
Time frame: baseline
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2025 (actual). Primary completion is estimated for Dec 2029, 50 months after the start.
Of 235 non-industry observational studies under Arthritis, Rheumatoid, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 122. This study's planned 50 months is above that.
Counting every sponsor, half of 390 studies reached it within 50 months; a quarter within 25 and three quarters within 113.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 1, 2026: primary completion Dec 2027 → Dec 2029 and completion Dec 2027 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Montpellier →